Jun 13, 2025

Red Teaming A Narrow Path: An Analysis of Phase 0 Policies for Artificial Superintelligence Prevention

Sky Bell

The report critically analyzes ControlAI's "A Narrow Path" Phase 0 policies, which aim to prevent Artificial Superintelligence (ASI) development for 20 years. Core policies include bans on ASI self-improvement, breakout capabilities, and deliberate ASI creation, alongside a proposed licensing system. The analysis identifies critical implementation challenges such as ambiguity in defining "superintelligence" and "forbidden capabilities," limitations of compute thresholds as reliable regulatory triggers, and the inherent difficulty in verifying the absence of dangerous capabilities in "black box" AI systems. Policy effectiveness is threatened by geopolitical competition fostering a "race to the bottom," the paradoxical risk of safety research inadvertently advancing dangerous capabilities, and the practical hurdles of enforcing international treaties against private actors. The report acknowledges alternative perspectives advocating for unrestricted AI development but focuses on strengthening ControlAI's framework for real-world legislative adoption and a feasible ASI moratorium.

The analysis employs a multi-faceted methodology, including historical case study analysis, comparative policy framework analysis, threat modeling, implementation feasibility assessment, and evidence gathering. Key findings reveal significant implementation feasibility gaps and policy effectiveness weaknesses. The report concludes that while ControlAI's framework is commendable for its proactive and comprehensive approach to existential risk, its ambition currently outstrips the technical, legal, and geopolitical realities of AI governance. Recommendations for strengthening the policies include adopting dynamic, capability-based regulation, investing in verifiable safety mechanisms, fostering strategic diplomacy and incentivized cooperation, and strengthening public sector capacity. The broader implications for AI governance are profound, highlighting the need for a nuanced approach that balances immediate risk mitigation with the long-term goal of safe, transformative AI.

Reviewer's Comments

Reviewer's Comments

Arrow
Arrow
Arrow

Overall, the writing is thoughtful. However, the objections are largely of the format of providing mitigators or caveats against the overall approach, and I'm not convinced that these are sufficient to constitute a fundamental problem to the Narrow Path plan. More detail to impact a fewer number of objections, rather than a broad shotgun approach, would likely have been more impactful here.

I don't think the ability to precisely define superintelligence is necessary given that that policy is normative and a guiding principle. Judges can literally say "I know a superintelligence development project when I see one", but also these details can be further worked out by regulators.

Static thresholds is a reasonable objection. In my opinion, Phase 0 indeed probably cannot prevent ASI for 20 years, the provisions of Phase 1 are needed too, including a mechanism to lower thresholds over time to account for algorithmic improvements.

To my knowledge we have not advocated in Phase 0 for the use of export controls - I agree about the geopolitical risk of these.

Investing in containment research and HEMs seems good as a suggestion.

Fostering diplomacy/cooperation also seems good. I'm not sold on if-then commitments - I think we already passed the point that a sensible and cautious civilization would have set if-then commitments at.

Agree on strengthening public sector capacity, but we already do this with establishment of AI regulators.

Overall quite good

Cite this work

@misc {

title={

(HckPrj) Red Teaming A Narrow Path: An Analysis of Phase 0 Policies for Artificial Superintelligence Prevention

},

author={

Sky Bell

},

date={

6/13/25

},

organization={Apart Research},

note={Research submission to the research sprint hosted by Apart.},

howpublished={https://apartresearch.com}

}

Recent Projects

Apr 27, 2026

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

Apr 27, 2026

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

Apr 27, 2026

PROTEUS (PROTein Evaluation for Unusual Sequences): Structure-Informed Safety Screening for de novo and Evasion-Prone Protein-Coding Sequences

AI protein design tools like RFdiffusion, ProteinMPNN, and Bindcraft make it trivial to produce low-homology sequences that fold into active, potentially hazardous architectures. However, sequence homology-based biosafety screening tools cannot detect proteins that pose functional risk through structurally novel mechanisms with no sequence precedent. We present a tiered computational pipeline that addresses this gap by combining MMseqs2 sequence alignment with structure-based comparison via FoldSeek and DALI against curated toxin databases totaling ~34,000 entries. AlphaFold2-predicted structures are screened for both global fold similarity (FoldSeek) and local active/allosteric site geometry (DALI), capturing convergent functional hazards that sequence screening misses. The pipeline was validated against a panel of toxins, benign proteins, structural mimics, and de novo-designed Munc13 binders, as well as modified ricin variants with residue substitutions. We additionally tested robustness to partial-synthesis evasion, where a bad actor submits multiple shorter coding sequences intended for downstream reassembly into a full toxin-coding gene. We found that while sequence-based screening did not identify any de novo ricin analogues with high certainty, the combined pipeline with FoldSeek and DALI identified all 24 tested de novo ricins as toxic.

Read More

Apr 27, 2026

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

Apr 27, 2026

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.
This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.